Dominantly Inherited Alzheimer Network (DIAN)
Washington University School of Medicine · with National Institute on Aging (NIA) · NCT00869817
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 700
- US sites recruiting
- 7
- Study start
- January 2009
- Record last updated
- October 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Conditions: Alzheimer's Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Written informed consent obtained from participant and collateral source prior to any study-related procedures.
- Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
- Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
- Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
- Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.
Exclusion Criteria
- Under age 18
- Medical or psychiatric illness that would interfere in completing initial and follow-up visits
- Requires nursing home level care
- Has no one who can serve as a study informant
Recruiting US locations
Mayo Clinic Jacksonville
Jacksonville, FL 32224
Site contact: Ercilia Moncayo · Moncayo.Ercilia@mayo.edu
Indiana University-Indiana Alzheimer Disease Center
Indianapolis, IN 46202
Site contact: Jill Buck, RN · 317-963-1847 · jilmbuck@iu.edu
Brigham and Women's Hospital
Boston, MA 02115
Site contact: Alexa Coussoule · acoussoule@bwh.harvard.edu
Washington University in St. Louis School of Medicine
St Louis, MO 63108
Site contact: McCrae Johnson, RN, MSN · mccrae@wustl.edu
University of Pittsburgh
Pittsburgh, PA 15260
Site contact: Zana Ikonomovic, MD · 412-692-2740 · ikonomovics@upmc.edu
Butler Hospital
Providence, RI 02906
Site contact: Courtney Bodge, PhD · (401) 455-6403 · cbodge@butler.org
University of Washington
Seattle, WA 98195
Site contact: Sarah Taylor · saraht73@uw.edu
Study contacts (from the official record)
- Alisha Daniels, MD,MHA · (314) 273-9057
- DIAN Obs Admin Core · NEURO-DIANCoordinatingCenter@email.wustl.edu
Similar studies in Florida
All neurology studies in Florida →- RecruitingHealthy volunteersPhase 1
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
Eli Lilly and Company
- Location
- Daytona Beach, FL
- Eligibility basics
- Ages 18–85
- RecruitingHealthy volunteersPhase 1
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
Prevail Therapeutics
- Location
- Naples, FL + 1 other US site
- Eligibility basics
- Ages 30–80
- RecruitingHealthy volunteersPhase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Eli Lilly and Company
- Location
- Naples, FL + 7 other US sites
- Eligibility basics
- Ages 30–85
- RecruitingHealthy volunteersPhase 1
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
Eli Lilly and Company
- Location
- Daytona Beach, FL
- Eligibility basics
- Ages 18–85